Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 4 | 2021 | 329 | 0.980 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 18 | 0.740 |
Why?
|
| Dioctyl Sulfosuccinic Acid | 1 | 2017 | 3 | 0.560 |
Why?
|
| Burkholderia cepacia complex | 1 | 2017 | 3 | 0.560 |
Why?
|
| Burkholderia Infections | 1 | 2017 | 7 | 0.560 |
Why?
|
| Drug Contamination | 1 | 2017 | 36 | 0.550 |
Why?
|
| Pneumonia, Viral | 1 | 2021 | 374 | 0.500 |
Why?
|
| Fellowships and Scholarships | 2 | 2015 | 277 | 0.500 |
Why?
|
| Specialization | 1 | 2015 | 75 | 0.480 |
Why?
|
| Curriculum | 2 | 2015 | 723 | 0.360 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 515 | 0.350 |
Why?
|
| Bacteremia | 2 | 2011 | 407 | 0.320 |
Why?
|
| Texas | 7 | 2021 | 3581 | 0.320 |
Why?
|
| Pediatrics | 2 | 2015 | 1154 | 0.320 |
Why?
|
| Fever of Unknown Origin | 2 | 2016 | 45 | 0.320 |
Why?
|
| Fluconazole | 2 | 2008 | 47 | 0.320 |
Why?
|
| Environmental Exposure | 1 | 2011 | 222 | 0.320 |
Why?
|
| Candidiasis | 2 | 2008 | 129 | 0.290 |
Why?
|
| Hospitals, Pediatric | 3 | 2021 | 775 | 0.260 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2006 | 65 | 0.250 |
Why?
|
| Disease Outbreaks | 3 | 2021 | 321 | 0.240 |
Why?
|
| Soft Tissue Infections | 1 | 2006 | 84 | 0.240 |
Why?
|
| Fusobacterium | 1 | 2003 | 4 | 0.220 |
Why?
|
| Antifungal Agents | 2 | 2008 | 289 | 0.220 |
Why?
|
| Fusobacterium Infections | 1 | 2003 | 14 | 0.220 |
Why?
|
| Calcaneus | 1 | 2003 | 8 | 0.220 |
Why?
|
| Foot Diseases | 1 | 2003 | 24 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 3 | 2006 | 2414 | 0.200 |
Why?
|
| Infant | 7 | 2021 | 12473 | 0.200 |
Why?
|
| Brucella melitensis | 1 | 2002 | 8 | 0.200 |
Why?
|
| Brucellosis | 1 | 2002 | 19 | 0.190 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2002 | 33 | 0.190 |
Why?
|
| Dermatomycoses | 1 | 2021 | 17 | 0.190 |
Why?
|
| Mucormycosis | 1 | 2021 | 26 | 0.180 |
Why?
|
| Osteomyelitis | 1 | 2003 | 205 | 0.180 |
Why?
|
| Infant, Newborn | 7 | 2021 | 8181 | 0.170 |
Why?
|
| Staphylococcal Infections | 3 | 2015 | 556 | 0.170 |
Why?
|
| Infection Control | 3 | 2021 | 159 | 0.150 |
Why?
|
| Intensive Care Units, Neonatal | 4 | 2011 | 319 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 1154 | 0.150 |
Why?
|
| Staphylococcus aureus | 2 | 2015 | 459 | 0.140 |
Why?
|
| Adolescent | 5 | 2021 | 19300 | 0.140 |
Why?
|
| Angiostrongylus cantonensis | 1 | 2016 | 9 | 0.130 |
Why?
|
| Strongylida Infections | 1 | 2016 | 15 | 0.130 |
Why?
|
| Critical Illness | 1 | 2021 | 598 | 0.130 |
Why?
|
| Child, Preschool | 4 | 2021 | 14042 | 0.130 |
Why?
|
| Logic | 1 | 2015 | 9 | 0.130 |
Why?
|
| Humans | 16 | 2021 | 124307 | 0.130 |
Why?
|
| Chlorhexidine | 1 | 2015 | 45 | 0.130 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2015 | 70 | 0.120 |
Why?
|
| Child | 6 | 2021 | 24435 | 0.120 |
Why?
|
| Models, Educational | 1 | 2015 | 74 | 0.120 |
Why?
|
| Cystic Fibrosis | 1 | 2017 | 257 | 0.110 |
Why?
|
| Career Choice | 1 | 2015 | 143 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1103 | 0.110 |
Why?
|
| Male | 10 | 2021 | 60964 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 1584 | 0.110 |
Why?
|
| Female | 10 | 2021 | 66236 | 0.100 |
Why?
|
| Faculty, Medical | 1 | 2015 | 262 | 0.100 |
Why?
|
| Bedding and Linens | 1 | 2011 | 7 | 0.100 |
Why?
|
| Hospital Design and Construction | 1 | 2011 | 7 | 0.100 |
Why?
|
| Bacillus | 1 | 2011 | 35 | 0.090 |
Why?
|
| Genotype | 1 | 2017 | 2551 | 0.090 |
Why?
|
| Young Adult | 2 | 2021 | 8974 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2021 | 16228 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 1891 | 0.080 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2008 | 38 | 0.070 |
Why?
|
| Candida albicans | 1 | 2008 | 76 | 0.070 |
Why?
|
| Premature Birth | 1 | 2011 | 384 | 0.070 |
Why?
|
| Infant, Very Low Birth Weight | 2 | 2005 | 170 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2008 | 119 | 0.070 |
Why?
|
| Mycoses | 1 | 2008 | 116 | 0.070 |
Why?
|
| Serratia Infections | 1 | 2006 | 4 | 0.060 |
Why?
|
| Serratia marcescens | 1 | 2006 | 10 | 0.060 |
Why?
|
| Risk Factors | 3 | 2011 | 10141 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2008 | 4731 | 0.060 |
Why?
|
| Methicillin Resistance | 1 | 2004 | 118 | 0.060 |
Why?
|
| Gestational Age | 2 | 2005 | 1161 | 0.060 |
Why?
|
| Infant, Premature, Diseases | 1 | 2004 | 241 | 0.050 |
Why?
|
| Rhizopus | 1 | 2021 | 10 | 0.050 |
Why?
|
| Incidence | 2 | 2008 | 3080 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2006 | 1185 | 0.050 |
Why?
|
| Doxycycline | 1 | 2002 | 117 | 0.050 |
Why?
|
| Rifampin | 1 | 2002 | 128 | 0.050 |
Why?
|
| Sepsis | 1 | 2004 | 479 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2002 | 386 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2006 | 12292 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2015 | 363 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2015 | 785 | 0.040 |
Why?
|
| Proteus mirabilis | 1 | 2016 | 12 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2016 | 90 | 0.030 |
Why?
|
| Meningitis | 1 | 2016 | 98 | 0.030 |
Why?
|
| Mupirocin | 1 | 2015 | 19 | 0.030 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2015 | 92 | 0.030 |
Why?
|
| Prednisone | 1 | 2016 | 274 | 0.030 |
Why?
|
| Multilocus Sequence Typing | 1 | 2015 | 56 | 0.030 |
Why?
|
| Eosinophilia | 1 | 2016 | 101 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 1254 | 0.030 |
Why?
|
| Program Development | 1 | 2015 | 186 | 0.030 |
Why?
|
| Medicine | 1 | 2015 | 97 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2015 | 175 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2008 | 1415 | 0.030 |
Why?
|
| Leadership | 1 | 2015 | 228 | 0.030 |
Why?
|
| Probability | 1 | 2008 | 323 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3575 | 0.010 |
Why?
|
| Coagulase | 1 | 2004 | 24 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 49 | 0.010 |
Why?
|
| Staphylococcus | 1 | 2004 | 70 | 0.010 |
Why?
|
| Gentamicins | 1 | 2004 | 95 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 156 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 1802 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 2020 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 582 | 0.010 |
Why?
|
| Hypoxia | 1 | 2004 | 248 | 0.010 |
Why?
|
| Hypotension | 1 | 2004 | 181 | 0.010 |
Why?
|
| Vancomycin | 1 | 2004 | 218 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2004 | 814 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 5105 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2008 | 3382 | 0.010 |
Why?
|
| Middle Aged | 1 | 2015 | 26451 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 34153 | 0.010 |
Why?
|
| Adult | 1 | 2015 | 29385 | 0.010 |
Why?
|